Skip to main
LGVN
LGVN logo

Longeveron (LGVN) Stock Forecast & Price Target

Longeveron (LGVN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Longeveron Inc's investigational product, Lomecel-B, demonstrates significant potential in treating serious conditions such as Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, and aging-related frailty, bolstered by industry-leading survival benefits evidenced during clinical trials. The company reported a remarkable 100% five-year transplant-free survival rate in Phase 1b trial participants, suggesting a strong likelihood of FDA approval if ongoing studies achieve their endpoints. Furthermore, a revised discounted cash flow analysis, reflecting an updated weighted average cost of capital, indicates substantial upside potential for the stock, highlighting confidence in Longeveron's innovative business model and therapeutic advancements.

Bears say

Longeveron Inc has experienced a significant stock depreciation of approximately 56% year-to-date, which may be attributed to various company-specific factors that could undermine investor confidence. Key financial risks include potential safety concerns arising from the clinical development of Lomecel-B for Hypoplastic Left Heart Syndrome, as well as the possibility of inadequate efficacy results from ongoing clinical trials. Furthermore, delays in securing necessary funding for clinical advancement and uncertainties surrounding regulatory approvals may contribute to market challenges and increase the likelihood of dilution, negatively impacting the company's overall financial outlook.

Longeveron (LGVN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Longeveron (LGVN) Forecast

Analysts have given Longeveron (LGVN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Longeveron (LGVN) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Longeveron (LGVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.